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SUMMARY: Public health authorities recommend that isolation precautions for influenza should be
continued for 7 days after illness onset or until 24 h after the resolution of symptoms, whichever event
lasts longer. However, little data are available regarding the duration of isolation for patients with 2009
pandemic H1N1 (pH1N1). We recruited patients with confirmed pH1N1 virus infection at a 2,000-bed
tertiary care center. Influenza viral loads from oropharyngeal swab specimens were serially determined
by reverse transcriptase quantitative polymerase chain reaction every other day, and the risk factors for
prolonged viral shedding were investigated. To evaluate the current recommendations for isolation
precautions, we measured the intervals between symptom onset and the last viral RNA detection, and
that between the last viral RNA detection and the point at which the patient was symptom-free for 24 h.
From November 2009 to January 2010, 26 patients were enrolled, and viral RNA was detected in more
than half of the eligible patients (10 of 19, 52.6z) for Æ7 days after symptom onset. While evaluating
the policy for lifting quarantine, we found that viral RNA was detected in 4 of 15 patients (26.7z) be-
yond the recommended duration of isolation. In conclusion, viral RNA was detected in a substantial
proportion of hospitalized patients even when they fulfilled the recommended conditions for lifting
quarantine, and we believe that more prudence is required in this aspect.
INTRODUCTION
Since April 2009, pandemic H1N1 has disseminated
globally with sustained human-to-human transmission
(1). However, the introduction of effective vaccination
and seasonal change decreased influenza activity in the
Republic of Korea as well as other countries such as the
United States. In Korea, the number of outpatient visits
for influenza-like illness (ILI) per 1,000 patients had
been 45.0 in the 45th week of 2009, and this number
dropped to 6.0 in the 3rd week of 2010 (2). Similarly, in
the United States, ILI outpatient visits had been 77.2 in
the 42nd week of 2009, and this number decreased to
19.0 in the 3rd week of 2010 (3). However, a major
cause of concern is that 2009 pandemic H1N1 (pH1N1)
might spread worldwide in the next few years since most
of the global population aged below 60 has very limited
immunity against pH1N1 virus (4,5). The case fatality
of pH1N1 is thought to be comparable with that of
seasonal influenza, and even viral kinetics did not reveal
any significant differences (6–10). Major health authori-
ties recommend that isolation precautions for patients
with influenza symptoms should be continued for 7 days
after illness onset or until 24 h after the resolution of
fever and respiratory symptoms, whichever event lasts
longer, while a patient is in a healthcare facility (11).
However, only few studies have evaluated these recom-
mendations. In this study, we prospectively observed
the viral kinetics of pH1N1 and evaluated the validity of
the current quarantine policy.
METHODS
Patients and specimen collection: This study was per-
formed in Seoul, the Republic of Korea, from Novem-
ber 2009 to January 2010 at a single, 2,000-bed tertiary
care center. Oropharyngeal swabs from the patients sus-
pected to have pH1N1 infection were collected as clini-
cal specimens of respiratory secretion. If the reverse
transcriptase quantitative polymerase chain reaction
(RQ-PCR) for pH1N1 was positive, a serial RQ-PCR
test was performed every other day until the test re-
vealed negative result, and another test was performed
on the next day for confirming the negative result. All
participants or legal guardians provided written in-
formed consent. This study was approved by the institu-
tional review board of the tertiary care center.
RQ-PCR: Total nucleic acid was extracted from each
oropharyngeal swab specimen in a virus transport medi-
um using the NucliSens easyMAG instrument 3
(bioM áerieux, Durham, N.C., USA) according to the
manufacturer's instruction.
RQ-PCR experiments were performed using the Real-
Time ready Influenza A/H1N1 Detection Set} (Roche
Diagnostics GmbH, Mannheim, Germany). Each 20-mL
PCR reaction mixture contained 5 mL of RNA extract, 3
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Fig. 1. Trends of initial viral load after symptom onset and
changes in viral load after treatment initiation. The initial viral
load decreased 2 days after symptom onset (closed square; P＝
0.060) and the post treatment viral load decreased at least 3
days after antiviral treatment initiation (open square; P＝
0.059) with borderline significance. Sx, symptom; Tx, treat-
ment.
ml of premixed probe/primer, 4 ml of 5× reaction
buffer, 0.4 ml of 50× enzyme mix, and 7.6 ml of water.
Thermal cycling was done on the LightCycler 480
instrument (Roche Diagnostics) under the following
conditions: reverse transcription for 8 min at 559C, ini-
tial denaturation for 30 s at 909C, and 45 cycles of 10 s
at 959C, 20 s at 609C, and 10 s at 729C.
For quantitative comparison, we used the positive
control material included in the RealTime ready In-
fluenza A/H1N1 Detection Set}, which contained plas-
mids with known copy numbers (2× 106 copies/mL) of
the amplification target. A series of 5 consecutive 10-
fold dilution equivalents from 2× 106 to 2× 101
copies/mL were prepared and run to generate calibra-
tion curves correlating with the RQ-PCR results of the
cycle threshold (Ct) value. The lower detection limit of
the assay was 1,000 copies/mL of nucleic acid, and the
viral titer of a specimen with an undetectable RQ-PCR
result was considered as 500 copies/mL.
Data analysis: We collected data for demographics,
underlying diseases, presenting symptoms, presence of
pneumonia at initial presentation, time interval between
symptom onset and antiviral treatment, total leukocyte
counts, absolute lymphocyte counts, blood urea nitro-
gen, serum creatinine, and viral load of pH1N1. The
presenting symptoms, i.e., nasal obstruction, sore
throat, cough, myalgia, fatigue, headache, and fever,
were scored on a 4-point scale. The sum of scores was
regarded as the severity of presenting symptoms as men-
tioned in a prior study (12).
The logarithmic value of the initial viral load was de-
termined by comparing the time intervals between
symptom onset and initial test. In addition, the relation-
ships between logarithmic value of initial viral load and
patient’s demographics, underlying diseases, presenting
symptoms, and the presence of pneumonia were investi-
gated. To assess the changes in viral load after antiviral
therapy, the mean logarithmic value of the viral load
was compared as the time interval between the initiation
of antiviral therapy and subsequent viral load measure-
ments.
To identify the risk factors for prolonged viral RNA
detection in pH1N1, patients with available serial viral
load data beyond 7 days after symptom onset were
selected, and the relationships between prolonged viral
RNA detection and patients demographics, underlying
diseases, severity of presenting symptoms, timing of an-
tiviral initiation after symptom onset (Ã48 h versus
À48 h), and the presence of pneumonia were investigat-
ed.
To evaluate the current recommendations for isola-
tion precautions of pH1N1 virus, we compared the data
for the last positive day of viral RNA detection and the
day when the patient fulfilled the criteria for lifting
quarantine, either at least 7 days after illness onset or 24
h after the resolution of fever and respiratory symp-
toms, whichever event lasted longer. Demographics, un-
derlying diseases, presenting symptoms, timing of an-
tiviral therapy, presence of pneumonia, and initial log
viral load were evaluated for their relationship with viral
RNA detection beyond the recommended isolation
period.
For statistical analysis, we compared the means for
continuous variables by using independent Student's t
tests and the proportions for categorical variables by us-
ing Fisher's exact test or Pearson's chi-square test. Sig-
nificance was set as P º 0.05 using 2-sided compari-
sons, and all statistical analyses were performed using
SAS version 9.1.3 (SAS Institute, Inc., Cary, N.C.,
USA).
RESULTS
Twenty-six patients were recruited during the study
period, and the mean follow-up duration was 6.81±
3.90 days. The mean time interval between the symptom
onset and the initial test for pH1N1 RQ-PCR was 1.84
± 1.82 days.
The mean log value of initial viral load was 5.52±
1.78 copies/mL. The initial viral load was not related to
underlying comorbidities, presence of pneumonia, and
severity of initial presenting symptoms (data not
shown). When the initial viral load was compared with
the log values of the time interval between symptom on-
set and initial test, the mean log value was lower in the
patients whose initial tests were performed more than 2
days after symptom onset, and the difference showed
with borderline significance (Fig. 1, closed square). All
the patients of our study population were prescribed
neuraminidase inhibitor oseltamivir, and the mean in-
terval between the pH1N1 test and initiation of antiviral
therapy was 0.35± 0.56 days. The viral loads tended to
decrease at least 3 days after the initiation of antiviral
therapy (Fig. 1, open square).
To identify the risk factors related to prolonged viral
RNA detection after symptom onset, 19 patients, whose
serial viral load data were known for more than 7 days
after symptom onset, were included for the analysis
(Table 1). Among these patients, 10 (52.6z) were
found to be shedding viral RNA from oropharynx for at
least 7 days after symptom onset. However, no sig-
nificant risk factor for prolonged viral RNA detection
was identified, while an initial presentation with pneu-
monia was more frequent among the patients who were
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Table 1. Comparison of patients categorized by duration of viral RNA detection after symptom onset and viral RNA detection beyond lifting
quarantine conditions
Duration of viral RNA detection
post symptom onset
Viral RNA detection
beyond lifting quarantine conditions
Ã6 days
(n＝ 9, 47.4z)
Æ7 days
(n＝ 10, 52.6z) P
No
(n＝ 11, 73.4z)
Yes
(n＝ 4, 26.7z) P
Demographics
Age 53.0±18.5 55.9±17.5 0.734 53.1±17.6 59.5±12.3 0.453
Sex (male:female) 3:6 6:4 0.370 4:7 4:0 0.077
Comorbidity
CHF/IHD 1 (11.1) 2 (20.0) 1.000 1 (9.1) 1 (25.0) 0.476
Prior CVA 4 (44.4) 0 0.033 3 (27.3) 0 0.516
Malignancy 1 (11.1) 2 (20.0) 1.000 3 (27.3) 0 0.516
Chronic liver disease 0 0 0 0
Renal disease 2 (22.2) 1 (10.0) 0.582 2 (18.2) 1 (25.0) 1.000
Immunosuppressive status 1 (11.1) 3 (30.0) 0.582 2 (18.2) 1 (25.0) 1.000
Chronic pulmonary disease 0 1 (10.0) 1.000 0 1 (25.0) 0.267
Diabetes mellitus 3 (33.3) 6 (60.0) 0.370 5 (45.5) 2 (50.0) 1.000
Presence of comorbidity 6 (66.7) 8 (80.0) 0.628 9 (81.8) 3 (75.0) 1.000
Presence of pneumonia 4 (44.4) 9 (90.0) 0.057 5 (45.5) 4 (100) 0.103
Sum of initial symptom scores 9.00±4.92 7.67±5.34 0.589 7.50±5.54 9.75±2.22 0.299
Initial laboratory parameters
Total leukocyte count (cells/mL) 8,408±3,774 8,633±5,832 0.927 9,630±5,287 9,530±2,598 0.963
Lymphocyte count (cells/mL) 801±346 985±296 0.242 802±344 1,205±272 0.053
Lymphocyte increase on D7 (cells/mL) 857±1,488 －51.1±431 0.136 797±1,411 30±332 0.163
Platelet count (cells/mL) 248,200±202,125 101,334±69,097 0.270 248,800±99,922 199,500±41,315 0.367
Blood urea nitrogen (mg/dL) 15.7±12.6 21.4±12.4 0.357 19.8±14.5 20.2±13.5 0.980
Creatinine (mg/dL) 1.7±2.5 2.5±3.8 0.585 1.80±2.22 3.84±1.80 0.310
Log10 viral load (copies/mL) 4.95±1.83 5.65±1.76 0.414 5.12±2.02 4.61±0.80 0.499
Antiviral Tx within 48 h of Sx onset 4 (44.4) 5 (50.0) 1.000 5 (45.5) 1 (25.0) 0.604
Variables are given as no. (z) unless otherwise specified.
Continuous variable are presented as mean±standard deviation.
CHF, congestive heart failure; IHD, ischemic heart disease; CVA, cerebrovascular accident; Tx, treatment; Sx, symptom.
Fig. 2. Mean viral loads after symptom onset (A) and proportions of patients with viral RNA detection (B) regard-
ing the recommended conditions for lifting quarantine. The median durations for viral RNA shedding were not
different between the two groups (P＝ 0.382, log rank test).
shedding viral RNA for more than 7 days, with the
difference showing borderline significance (90.0z, 9/10
versus 44.4z, 4/9; P＝ 0.057). A history of prior
cerebrovascular accident (CVA) was less frequent
among patients with prolonged viral RNA detection
(0z, 0/10 versus 44.4z, 4/9; P＝ 0.033).
In the evaluation of the policy for lifting quarantine,
11 of 26 patients were excluded from the analysis. Six
patients discontinued their follow-up while they were
shedding viral RNA within 7 days after symptom onset,
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and 4 patients were not eligible for evaluation because
of concomitant infections from organisms such as
Mycobacterium tuberculosis or proven bacterial pneu-
monia. Another patient underwent liver transplantation
a month before pH1N1 diagnosis and had related
comorbidities, and therefore, the onset of symptoms
was not measurable in this patient and he was excluded
from the analysis. Among the 15 eligible patients, 4
(26.7z) were found to be shedding viral RNA when
they satisfied the usual recommended conditions for
lifting quarantine (Table 2, Fig. 2A). The median dura-
tion of viral RNA shedding in the group that showed
prolonged viral RNA detection after lifting the quaran-
tine conditions was slightly longer than that in the group
that did not show viral RNA after the quarantine condi-
tions (11.0 days versus 7.8 days), although the differ-
ence was not statistically significant (P＝ 0.382, log
rank test, Fig. 2B). There was no identifiable significant
risk factor with respect to the risk factors related for
viral RNA shedding after fulfilling the conditions for
lifting quarantine. However, an initial presentation of
pneumonia was more frequent among the patients who
were shedding viral RNA after fulfilling the conditions
for lifting quarantine (100z, 4/4 versus 45.5z, 5/11),
although the difference was not statistically significant
(P＝ 0.103).
DISCUSSION
The duration of influenza virus shedding has been an
issue of concern, especially in hospitalized patients,
because it is related to infection control measures such
as isolation and the use of surgical masks. Although
resistance to antiviral agents is a matter of concern
(13,14), antiviral stockpiling still remains an important
strategy for the epidemiologic control of a future pan-
demic, even with the availability of a safe and effective
pH1N1 vaccine (8). The natural kinetics of viral shedd-
ing of influenza A and the effect of antiviral therapy
have been well-described through a randomized con-
trolled study of experimental human infection (15). In
this randomized study, the median time to cessation of
viral shedding reduced from 107 h in the control group
to 58 h in the oseltamivir treatment group. However, in
one study, the proportions of patients with viral RNA
detection were similar for up to 7 days regardless of
oseltamivir treatment, although antiviral therapy
reduced the duration and severity of acute influenza-
related symptoms (17); these results were obtained in
previously healthy young individuals who were natural-
ly infected with the influenza virus. In our study, it was
not until after 3 days of antiviral treatment that the viral
load began to decrease. Although it is different from the
studies performed in a healthy study population, which
revealed a rapid decrease of viral load within 2 days af-
ter treatment (9,15,18), several studies revealed similar
viral kinetics of delayed decrease or clearance despite
antiviral therapy among pH1N1 patients with severe
pneumonia or oxygen desaturation (º90z) (6,20,21).
In the assessment of the initial viral load, the mean
value was relatively lower when the first RQ-PCR test
was performed more than 2 days after the symptom on-
set, and this is in accordance with prior studies that re-
vealed that the viral titer peaked about 24–48 h after
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symptom onset (15,19,22). In addition to the initial viral
load, the mean lymphocyte count also tended to be
higher in the group showing prolonged viral RNA detec-
tion. This is in contrast to the results of previous stu-
dies, since lymphocytopenia is a known risk factor for
hypoxemia (6), prolonged infection (23), or respiratory
failure (24). However, the increase in lymphocyte count
during the 7 days after pH1N1 diagnosis was impaired
in the groups showing prolonged viral RNA shedding in
our study.
We used RQ-PCR not only to quantify the relative
amount of viral RNA shedding but also to document the
presence of viral material as an indirect index of infec-
tivity. Viral culture is a superior method for the assess-
ing the infectivity of a virus, and influenza virus culture
study was positive only in about half of the patients
showing positive results in the RQ-PCR assay (16).
However, RQ-PCR has been accepted as the standard
method for pH1N1 infection diagnosis and we think
that the presence of a viral RNA can be used as the in-
direct index of virus infectivity. Major public health
authorities recommend that isolation precautions for
hospitalized patients with influenza symptoms should
be continued for 7 days after the illness onset or for 24 h
after the resolution of the fever and respiratory symp-
toms, whichever event is longer (11). This may be in-
ferred from previous studies, which showed that in-
fluenza virus shedding generally diminishes over the
course of 7 days (22), and viral clearance correlates with
symptom resolution (16,25,26). However, most of these
studies have focused on the viral dynamics of the initial
phase and early response to antiviral therapy rather than
the conditions for lifting quarantine, especially among
hospitalized patients. Lee et al. (12) observed that
hospitalized patients might show a high viral load as
well as prolonged viral shedding, and they suggested a
more stringent infection control strategy. However,
there has been no report validating the policy of lifting
quarantine for influenza infection with regard to both
the duration of viral shedding after symptom onset and
the condition of the patient's improvement. Viral
shedding from asymptomatic patients after recovery
from pandemic influenza is not a rare phenomenon
(27). A recent study by Witkop et al. reported that 24z
of the patients were shedding viable pH1N1 virus 7 days
after symptom onset and 19z of those who were
asymptomatic for more than 24 h were still found to
shed viable virus (7). This is concordant with our study
results, although in their study, different conditions
were applied for patients 7 days after symptom onset
and for those who had been symptom free for more
than 24 h. Moreover, their study population comprised
young healthy cadet trainees. In our study, 4 of 15
patients (26.7z) were found to be shedding the pH1N1
viral RNA when they satisfied the usually recommended
conditions for lifting quarantine. Although we could
not identify significant risk factors related to prolonged
viral RNA detection after lifting the quarantine condi-
tions, the frequency of accompanied pneumonia at ini-
tial presentation was more common in the patient group
that showed prolonged viral RNA detection; however,
the difference was not statistically significant.
Our work has several limitations. First, as mentioned
before, we did not use a virus culture method, which is
more relevant to determine the infectivity of virus. In
addition, the small number of patients in our study
population might have resulted in insufficient study
data, and this may be related to a failure to identify sig-
nificant risk factors for prolonged viral RNA detection
after lifting of quarantine conditions.
In summary, a substantial proportion of pH1N1 in-
fected hospitalized patients were shedding detectable
viral RNA when they fulfilled the conditions for lifting
quarantine. Further investigation regarding this result is
crucial since the nosocomial spread of influenza is a crit-
ical issue in the management of influenza pandemic.
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